Clinical trials: Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancinoma (NPC)
Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC
This Phase III multicenter trial investigates treatment intensification for high-risk, stage T1-2N1M0 nasopharyngeal carcinoma. Patients with high-risk features (>3 metastatic lymph nodes, necrosis, or confluence) receive…
- Trial name
- NCT07248670
- Testing
- metronomic adjuvant chemotherapy with capecitabine
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Chongqing University Cancer Hospital
Nasopharyngeal Carcinoma
Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma（NPC）is common malignant tumor in China. The incidence of NPC in most parts of the world and the country is less than 1/10 million, but the incidence rate in China's Guangdong, Guangxi, Fujian and other…
- Trial name
- NCT05292027
- Testing
- low-dose radiotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Nasopharyngeal Cancinoma (NPC)
Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy
The goal of this phase I clinical trial is to evaluate the safety and feasibility of a multimodal evaluation-guided surveillance-intervention strategy in patients with newly diagnosed N3 nasopharyngeal carcinoma.
- Trial name
- NCT07636499
- Testing
- Multimodal Evaluation-Guided Surveillance-Intervention Strategy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guiquan Zhu
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
- Trial name
- NCT06749899
- Testing
- QL1706, Gemcitabine, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 580 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Nasopharyngeal Cancinoma (NPC)
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
This phase II randomized trial compares the efficacy and safety of Toripalimab combined with three different platinum-based induction chemotherapy regimens, sequentially followed by standard concurrent chemoradiotherapy, for the…
- Trial name
- NCT07362979
- Testing
- GP plus Toripalimab Induction chemotherapy+CCRT, TP plus Toripalimab Induction chemotherapy+CCRT, TPC plus Toripalimab Induction chemotherapy+CCRT
- Where
- 4 sites in China
- Volunteers
- 243 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy with becotatug vedotin (MRG003) plus pucotenlimab, followed by treatment allocation based on…
- Trial name
- NCT07524413
- Testing
- Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy
- Volunteers
- 298 people
- Sponsor
- Sun Yat-sen University
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
- Conditions
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT05910827
- Testing
- HMBD-001, Docetaxel, Cetuximab
- Where
- 20 sites in Australia, Moldova and 3 more
- Volunteers
- 398 people
- Sponsor
- Hummingbird Bioscience
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.
- Trial name
- NCT07067268
- Testing
- Adjuvant therapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Nasopharyngeal Cancinoma (NPC)
Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
This multicenter randomized controlled Phase III trial assesses the efficacy and safety of becotatug vedotin plus anti-PD-1 antibody as maintenance therapy for recurrent/metastatic nasopharyngeal carcinoma.
- Trial name
- NCT07705243
- Testing
- Anti-PD1, Anti-PD1 combined with Becotatug Vedotin
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells.
- Trial name
- NCT07138989
- Testing
- Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Intensity-modulated Radiotherapy
IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
This observational study aims to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone in patients with stage IB nasopharyngeal carcinoma (NPC) without high-risk features.
- Conditions
- Nasopharyngeal Cancinoma (NPC), Intensity-modulated Radiotherapy, Stage IB
- Trial name
- NCT07376603
- Testing
- IMRT along
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Qiaojuan Guo
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II…
- Trial name
- LIGHT (NCT07325539)
- Testing
- Gemcitabine(GEM), Cisplatin, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Conditions
- Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
- Trial name
- NCT06802835
- Testing
- EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma
This study investigates whether administering reduced dose is non-inferior to standard dose radiotherapy in terms of 3-year locoregional relapse-free survival (LRRFS) rate for stage I nasopharyngeal carcinoma patients who are…
- Trial name
- NCT06912698
- Testing
- Reduced dose radiation, Standard dose radiation
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Hai-Qiang Mai,MD,PhD
Nasopharyngeal Cancinoma (NPC)
Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients
Nasopharyngeal cancer is the sixth most common cancer and the sixth leading cause of death in Indonesia. NPC is a radiosensitive cancer so radiotherapy is the basic therapy for NPC.
- Trial name
- NCT07042711
- Testing
- Vitamin D 5,000IU Oral Tablet
- Where
- Indonesia
- Volunteers
- 300 people
- Sponsor
- Universitas Indonesia
Nasopharyngeal Cancinoma (NPC)
Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial
This study is aimed to evaluate the efficacy and safety of tislelizumab combined with chemotherapy and response-adapted radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma
- Trial name
- NCT07248696
- Testing
- response-adapted radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Chongqing University Cancer Hospital
Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
This single-center, Phase 1 study is evaluating the safety, tolerability, and preliminary antitumor activity of recombinant human endostatin adenovirus injection (EDS01) given by intratumoral injection in combination with…
- Trial name
- EDS01 HN (NCT07625423)
- Testing
- EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Nasopharyngeal Cancinoma (NPC)
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.
- Trial name
- NCT06669611
- Testing
- Camrelizumab combined GP chemotherapy, Camrelizumab combined TPC chemotherapy
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
This trial aim to explore whether short-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 3 cycles of 400 mg q6w in the consolidation phase) yields non-inferior event-free survival compared to long-course…
- Trial name
- NCT07373990
- Testing
- tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2)
- Volunteers
- 418 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC
The goal of this phase 3 non-inferiority trial is to compare the efficacy and toxicity of proton or photon radiation therapy plus carbon ion radiation therapy for newly diagnosed nasopharyngeal carcinoma.
- Trial name
- NCT06846450
- Testing
- Intensity-modulated proton radiation therapy, Intensity-modulated photon radiation therapy, Intensity-modulated carbon ion radiation therapy
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Lin Kong, MD